Acorda's much-needed Inbrija hits a snag at the FDA by Eric Sagonowsky Thursday, September 13, 2018 After losing a last-ditch court battle against Ampyra generics, Acorda now faces an FDA delay on its new Parkinson's drug Inbrija.
Acorda desperately needs Inbrija nod after appeals loss by Eric Sagonowsky Tuesday, September 11, 2018 Acorda faces the prospect of generic competition on its primary revenue source, Ampyra, after an appeals court's decision.
CEO: Win or lose on Ampyra, Acorda's reps are safe with Inbrija by Carly Helfand Wednesday, June 6, 2018 Even if Acorda loses its upcoming appeal on Ampyra's patents, its sales force won’t have to worry, CEO Ron Cohen says.
